<DOC>
	<DOCNO>NCT01709474</DOCNO>
	<brief_summary>The primary objective study evaluate effect 18 week high-dose vitamin D3 supplementation compare standard-dose vitamin D3 supplementation immune function , glucose homeostasis , bone metabolism child systemic lupus erythematosus ( SLE ) serum 25-hydroxyvitamin D [ 25 ( OH ) D ] level ≤20 ng/mL .</brief_summary>
	<brief_title>Vitamin D3 Treatment Pediatric Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This multi-center , phase II , 18-week , two arm , unblinded randomized clinical trial . Seventy-eight pediatric subject SLE 25 ( OH ) D level ≤ 20 ng/mL randomize 1:1 ratio receive either standard-dose ( 400 IU/day ) high-dose ( 6,000 IU/day ) vitamin D3 18 week base upon weight baseline . Subjects randomize high-dose vitamin D3 treatment arm receive 6,000 IU per day baseline subject 's vitamin D level reach ≥ 40 ng/mL point vitamin D3 dose reduce 4,000 IU per day . Subjects randomize high-dose treatment arm weigh &lt; 40 kg receive supplementation five day per week subject receive supplementation seven day week . In addition baseline , week 6 , 12 , 18 visit , subject randomize high-dose treatment arm return Weeks 3 9 ass symptom vitamin D toxicity . If subject high-dose arm find exhibit evidence vitamin D toxicity week 12 visit , he/she ask return clinical research site additional vitamin D toxicity assessment week 15 . Study personnel record subject 's interval history , assess adverse event , disease activity , collect sample safety mechanistic assessment .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Written inform consent sign subject parent/guardian appropriate ; child assent appropriate ; Before age 19 , meet least 4 11 modified American College Rheumatology ( ACR ) 1982 Revised Criteria Classification Systemic Lupus Erythematosus updated 1997 ; Date SLE diagnosis ( described Inclusion Criterion 2 ) least 24 week prior randomization ; Serum 25hydroxyvitamin D [ 25 ( OH ) D ] &lt; 20 ng/mL Screening ; SELENA SLEDAI score &gt; 0 &lt; 8 Screening Baseline ; If take prednisone ( equivalent corticosteroid ) , dose must ≤ 15 mg/day ≤0.5 mg/kg/day , whichever low , stable least four week prior randomization . Note , subject take steroid every day , divide dose 2 evaluate eligibility ; Stable immunosuppressive dose least 12 week prior randomization ; Immunosuppressive medication allow include mycophenolate ( MMF ) , azathioprine , methotrexate , antimalarial medication ( e.g. , hydroxychloroquine ) , cyclosporine A ( CsA ) , tacrolimus , intravenous immune globulin ( IVIG ) , abatacept . Body weight &gt; 25 kg ; Able swallow pill ; Males females reproductive potential must agree practice effective measure birth control . Any condition treatment , opinion investigator , place subject unacceptable risk participant trial ; Current pharmacologic vitamin D2 D3 intake &gt; 800 IU daily use calcitriol dose past four week prior randomization ; Cyclophosphamide IV glucocorticoid exposure within 12 week prior randomization ; Any BILAG A B manifestation exception BILAG B mucocutaneous manifestation screening , exclude renal BILAG criterion ( see rituximab belimumab criterion , ) ; Significant renal insufficiency define : Estimated GFR &lt; 60 mL/min/1.73m^2 estimate GFR &lt; 90 mL/min/1.73m^2 reduction GFR &gt; 15 % last measurement ; Urine dipstick value 2+ high protein , unless stable value last measurement , urine proteincreatinine ratio ≥ 50 mg/mmol unless value represent improvement ≥ 25 % last measurement . Rituximab belimumab exposure use within 24 week prior randomization ; The following laboratory parameter Screening visit : Platelets &lt; 50,000 ; WBC &lt; 2,500 ; ANC &lt; 1,000 ; Hemoglobin &lt; 9 mg/dL ; ALT , AST , bilirubin &gt; 2x upper limit normal ( ULN ) ; Hypercalcemia ( calcium &gt; ULN ) ; Hypercalciuria ( urinary calcium/creatinine ratio &gt; 0.2 ) . Primary hyperparathyroidism ( know ) ; History nephrolithiasis ( know ) ; Diabetes mellitus require insulin therapy ; Medications interfere vitamin D absorption ; History vertebral compression fracture ( know ) ; Pregnancy ( girl ≥ 11 year age must negative urine/serum pregnancy test ) ; A history nonadherence/noncompliance ; Other investigational drug and/or treatment four week seven halflives investigational drug prior start study product dosing ( Day 0 ) , whichever great length time enrollment ; Current diagnosis cancer chronic infection Hepatitis B , Hepatitis C , tuberculosis ; Treatment digoxin ; Flu ( influenza ) vaccination within one week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>SLE</keyword>
	<keyword>Vitamin D3</keyword>
	<keyword>Vitamin D deficiency</keyword>
	<keyword>IFN alpha expression</keyword>
</DOC>